Review article: new treatments in non‐alcoholic fatty liver disease
Alimentary Pharmacology & Therapeutics2017Vol. 46(5), pp. 494–507
Citations Over TimeTop 10% of 2017 papers
Abstract
Rising demand and an improved understanding of NASH pathophysiology has led to a surge in development of new therapies. Tailoring pharmacotherapy to the dominant pathogenic pathway in a given patient along with use of combination therapy is likely to represent the future direction in treatment of patients with NASH.
Related Papers
- → The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement(2017)251 cited
- → Treatment of non‐alcoholic fatty liver disease(2013)20 cited
- → LPSF/GQ-02 Inhibits the Development of Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Fatty Liver Disease (NAFLD)(2015)16 cited
- → The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease(2014)8 cited
- [Non-alcoholic fatty liver disease: age peculiarities, breakthrough in pathogenetic therapy].(2009)